NYSE:VOR

Vor Biopharma News Headlines

$4.22

-0.18 (-4.09%)

(As of 05/13/2022 04:00 PM ET)

Add

Compare

Today's Range: $4.13
▼
$4.58
50-Day Range: $4.22
▼
$8.65
52-Week Range: $4.13
▼
$23.96

Volume: 85,189 shs
Average Volume: 105,920 shs
Market Capitalization: $158.29 million

P/E Ratio: N/A
Dividend Yield: N/A
Beta: -0.38

Get Vor Biopharma News Delivered to You Automatically

Media Mentions By Week

Vor Biopharma Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

VOR
News Sentiment
▼
-0.02

0.48
▲
Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

VOR Articles
This Week
▼
4

1
▲
VOR Articles
Average Week

Vor Biopharma (NYSE:VOR) News Headlines Today

Source

Source	Headline
	Vor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of "Buy" by Analysts marketbeat.com - May 15 at 8:45 AM
	JMP Securities Cuts Vor Biopharma (NYSE:VOR) Price Target to $15.00 marketbeat.com - May 13 at 12:23 PM
	Expert Ratings for Vor Biopharma markets.businessinsider.com - May 13 at 1:31 PM
	We Think Vor Biopharma (NASDAQ:VOR) Can Afford To Drive Business Growth finance.yahoo.com - May 7 at 1:12 PM
	Kedrion Biopharma tilgt 200 Millionen Euro seiner 2022 fälligen Anleihen finanznachrichten.de - May 2 at 8:14 AM
	Vor Biopharma initiated at neutral at Goldman as value proposition yet to be determined seekingalpha.com - April 27 at 1:07 PM
	Was hat Elon Musk mit Twitter vor? - Viele offene Fragen nach Übernahme msn.com - April 26 at 2:56 PM
	Vor Bio Announces Retirement of Chief Medical Officer finance.yahoo.com - April 14 at 8:45 PM
	Akron BioProducts and Vor Bio to Collaborate on the Development and cGMP Manufacture of Nucleases finance.yahoo.com - March 22 at 4:15 PM
	Barclays Maintains Overweight on Vor Biopharma, Lowers Price Target to $26 benzinga.com - March 21 at 9:30 AM
	Vor Bioipharma files for $350M mixed shelf offering seekingalpha.com - March 14 at 10:53 PM

	Vor Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update finance.yahoo.com - March 14 at 5:52 PM
	Alvotech und Fuji Pharma erweitern ihre Zusammenarbeit um zusätzlichen Biosimilar-Kandidaten in Japan de.finance.yahoo.com - February 24 at 7:41 AM
	Vor to Participate in the 11th Annual SVB Leerink Global Healthcare Conference finance.yahoo.com - February 11 at 9:08 AM
	Vor Biopharma Inc. Common Stock (VOR) nasdaq.com - January 20 at 8:02 PM
	Vor Biopharma Inc Shares Approach 52-Week Low - Market Mover nasdaq.com - January 8 at 9:41 AM
	Vor Biopharma shares are trading higher after HC Wainwright initiated coverage on the stock with a Buy rating and $26 price target. benzinga.com - December 17 at 3:08 PM
	Vor to Participate in the JMP Securities Hematology and Oncology Summit finance.yahoo.com - November 29 at 10:32 AM
	Vor Biopharma Insider Sold Over $5.0M In Company Stock benzinga.com - November 19 at 1:33 PM
	Does Vor Biopharma (VOR) Have the Potential to Rally 186% as Wall Street Analysts Expect? finance.yahoo.com - November 15 at 3:02 PM
	We're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash Wisely finance.yahoo.com - November 11 at 3:45 PM
	Vor Reports Third Quarter 2021 Financial Results and Provides Company Update finance.yahoo.com - November 10 at 7:02 PM
	Vor to Present New Data on its Cell and Genome Engineering Platform at SITC Annual Meeting finance.yahoo.com - November 9 at 8:48 AM
	Vor to Participate in Two Upcoming Investor Conferences finance.yahoo.com - November 8 at 8:31 AM
	Vor to Present New Platform and Preclinical Data at ASH finance.yahoo.com - November 4 at 9:27 AM
	Vor to Present Data from its Novel Cell and Genome Engineering Platform at ESGCT finance.yahoo.com - October 19 at 7:35 AM
	Vor Strengthens Leadership Team with Addition of Dr. Veit Schmelmer as SVP of Program and Alliance Management finance.yahoo.com - October 12 at 9:13 AM
	Enara Bio announces the appointment of highly experienced biotech executive Dr. Robert Ang to its Board of Directors finance.yahoo.com - September 28 at 7:30 AM
	Vor Biopharma Says FDA Grants Fast Track Designation To VOR33 For Acute Myeloid Leukemia nasdaq.com - September 10 at 3:35 AM
	Vor Biopharma's Lead Hematopoietic Stem Cell Candidate Fast Tracked In US markets.businessinsider.com - September 9 at 12:31 PM
	VOR33 Granted U.S. FDA Fast Track Designation for AML finance.yahoo.com - September 9 at 12:31 PM
	Vor to Participate in Three Upcoming Investor Conferences finance.yahoo.com - September 2 at 8:59 AM
	Cresa Boston Assists Vor Biopharma to Expand Its Footprint and Create In-house Clinical Manufacturing Facility markets.businessinsider.com - August 24 at 4:40 PM

	Vor Biopharma Inc. barrons.com - August 20 at 5:53 PM
	Vor Reports Second Quarter 2021 Financial Results and Provides Company Update finance.yahoo.com - August 9 at 6:13 PM
	BRIEF-Puretech Founded Entity Vor Biopharma Announces Collaboration With Janssen To Develop Engineered Hematopoietic Stem Cell Transplants Combined With A Bi-Specific Antibody ... msn.com - July 9 at 9:41 AM
	Vor Biopharma Working With Janssen Biotech on Leukemia Treatment marketwatch.com - July 9 at 9:41 AM
	Vor Biopharma, Janssen Team Up To Develop Combination Therapies For Acute Myeloid Leukemia markets.businessinsider.com - July 8 at 1:38 PM
	The Petri Dish: Moderna launches flu trial, Vor teams with Janssen bizjournals.com - July 8 at 8:38 AM
	BRIEF-Vor Biopharma Announces Collaboration With Janssen To Develop Treatment For Acute Myeloid Leukemia (Aml) msn.com - July 8 at 8:38 AM
	Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined With a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML) finance.yahoo.com - July 8 at 8:38 AM
	Vor to Build-Out State-of-the-Art Clinical Manufacturing Facility Capable of Supporting Multiple Cell Therapy Programs finance.yahoo.com - June 17 at 8:18 AM
	Vor Biopharma Names Matthew Patterson Board Chair marketwatch.com - June 11 at 9:21 AM
	Vor Biopharma Shares Rise 9% on License Agreement With Abound Bio marketwatch.com - June 10 at 6:38 PM
	Vor Biopharma, Abound Bio in Licensing Agreement for Leukemia Treatment marketwatch.com - June 10 at 1:37 PM
	Vor to Develop Multi-Targeted CAR-Ts with Abound Bio finance.yahoo.com - June 10 at 8:37 AM
	Vor Biopharma to Present at Jefferies and Goldman Sachs Investor Conferences finance.yahoo.com - May 25 at 8:03 PM
	How Many Vor Biopharma Inc. (NASDAQ:VOR) Shares Do Institutions Own? finance.yahoo.com - May 7 at 8:23 PM
	Vor Reports First Quarter 2021 Financial Results and Provides Company Update finance.yahoo.com - May 6 at 4:43 PM
	Vor To Present on VOR33 Manufacturing Scale-Up and Off-Target Editing at ASGCT finance.yahoo.com - April 28 at 10:05 AM
	Vor Biopharma Inc reuters.com - March 30 at 10:32 PM
	Vor Biopharma Reports FY20 Net Loss Of $43.3M Compared To $10.8M YoY benzinga.com - March 25 at 8:48 PM

Get Vor Biopharma News Delivered to You Automatically

This page was last updated on 5/15/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources